Morgan Stanley Sticks to Its Buy Rating for Samvardhana Motherson International Limited (MOTHERSON)
Confident Investing Starts Here:
Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
According to TipRanks, Singh is a 2-star analyst with an average return of 1.9% and a 63.64% success rate. Singh covers the Consumer Cyclical sector, focusing on stocks such as Bajaj Auto Limited, Eicher Motors Limited, and Hero Motocorp Limited.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Samvardhana Motherson International Limited with a INR154.67 average price target, a 1.01% upside from current levels. In a report released on May 30, CLSA also maintained a Buy rating on the stock with a INR182.00 price target.
The company has a one-year high of INR217.00 and a one-year low of INR107.30. Currently, Samvardhana Motherson International Limited has an average volume of 1.09M.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
2 hours ago
- Yahoo
Mckesson lifts annual profit forecast on robust demand for specialty drugs
(Reuters) -U.S. drug distributor McKesson raised its annual profit forecast and beat Wall Street earnings estimates on Wednesday, banking on robust demand for specialty medicines. High profit margins for specialty medicines, which treat complex conditions such as rheumatoid arthritis and cancer, have encouraged companies to expand in the market. Texas-headquartered Mckesson expects per-share profit in the range of $37.10 to $37.90 for fiscal 2026, compared to its previous expectation of $36.90 to $37.70. Analysts on average expect a profit of $37.41 per share, according to data compiled by LSEG. Earlier in the day, peer Cencora also raised its annual profit forecast and posted quarterly earnings that topped Wall Street estimates. Mckesson reported first-quarter revenue of $97.83 billion, beating analysts' average estimate of $96.08 billion. The company said it benefited from increased prescription volumes from retail national account customers, growth in the distribution of specialty products and contributions from acquisitions. On an adjusted basis, McKesson earned $8.26 per share, compared with estimates of $8.15. The drug distributor's U.S. pharmaceutical unit — its largest segment by revenue — recorded sales of $89.95 billion. That was 25% higher than the year earlier and beat analysts' estimate of $89.52 billion. Last quarter, Mckesson said it would spin off its medical-surgical solutions unit into an independent company to focus on its core drug distribution business. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
3 hours ago
- Yahoo
Sana Biotechnology Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
SEATTLE, Aug. 06, 2025 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (Nasdaq: SANA) ('Sana'), a company focused on changing the possible for patients through engineered cells, today announced that it has commenced an underwritten public offering of $75.0 million of shares of its common stock and, in lieu of common stock to certain investors, pre-funded warrants to purchase shares of its common stock. In addition, Sana intends to grant the underwriters a 30-day option to purchase up to an additional $11.25 million of shares of its common stock. All of the shares of common stock and pre-funded warrants to be sold in the proposed offering will be sold by Sana. The proposed offering is subject to market and other conditions, and there can be no assurance as to whether or when the proposed offering may be completed, or as to the actual size or terms of the proposed offering. Morgan Stanley, Goldman Sachs & Co. LLC, BofA Securities, and TD Cowen are acting as joint book-running managers for the proposed offering. The proposed offering is being made pursuant to a Registration Statement on Form S-3, including a base prospectus, previously filed with and declared effective by the SEC, and Sana will file a preliminary prospectus supplement and accompanying prospectus relating to and describing the terms of the proposed offering, copies of which can be accessed for free through the SEC's website at When available, copies of the preliminary prospectus supplement and the accompanying prospectus relating to the proposed offering may also be obtained from: Morgan Stanley & Co. LLC, Attention: Prospectus Department, 180 Varick Street, 2nd Floor, New York, NY 10014 or by email at prospectus@ Goldman Sachs & Co. LLC, Attn: Prospectus Department, at 200 West Street, New York, NY 10282, by telephone at (866) 471-2526 or by email at prospectus-ny@ BofA Securities, Attn: Prospectus Department, NC1-022-02-25, 201 North Tryon Street, Charlotte, NC 28255-0001 or by email at or TD Securities (USA) LLC, 1 Vanderbilt Avenue, New York, New York 10017, by telephone at (855) 495-9846 or by email at This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor will there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation, or sale would be unlawful before registration or qualification under the securities laws of any such state or jurisdiction. About Sana Biotechnology Sana Biotechnology, Inc. is focused on creating and delivering engineered cells as medicines for patients. Sana has operations in Seattle, WA, Cambridge, MA, and South San Francisco, CA. Cautionary Note Regarding Forward-Looking Statements This press release contains forward-looking statements about Sana Biotechnology, Inc. (the 'Company,' 'we,' 'us,' or 'our') within the meaning of the federal securities laws, including those related to the completion, timing, and size of the proposed offering and our intent to grant the underwriters a 30-day option to purchase additional shares. These forward-looking statements are neither promises nor guarantees and are subject to a variety of risks and uncertainties, including but not limited to: whether or not we will be able to raise capital through the sale of securities or consummate the offering; the final terms of the offering; the satisfaction of customary closing conditions; prevailing market conditions; general economic and market conditions as well as geopolitical developments; and other risks. Information regarding the foregoing and additional risks may be found in the section entitled 'Risk Factors' in documents that we file from time to time with the Securities and Exchange Commission, including the registration statement and the preliminary prospectus supplement relating to the proposed public offering. These forward-looking statements are made as of the date of this press release, and we assume no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. Investor Relations & Media: Nicole in to access your portfolio
Yahoo
5 hours ago
- Yahoo
Why Arista Networks Stock Is Skyrocketing Wednesday
Arista Networks Inc. (NYSE:ANET) reported better-than-expected second-quarter financial results after markets closed on Tuesday. Revenues increased 30.4% year over year $2.21 billion, versus estimates of $2.11 billion and the management guidance of $2.1 billion. Adjusted EPS jumped to 73 cents from 53 cents a year ago, versus estimates of 65 cents. Gross margin was 65.2% in the second CFO, Chantelle Breithaupt, said, 'Non-GAAP operating income crossed $1 billion for the first time at Arista...' View more earnings on ANET Arista Networks expects third-quarter sales of $2.25 billion versus the consensus of $2.093 billion. Analysts' Reaction Following the impressive earnings report and upbeat guidance, several prominent financial institutions reiterated their positive stance on Arista Networks. Morgan Stanley maintained an Overweight rating, raising its price forecast from $120 to $125. Piper Sandler, while holding a Neutral rating, significantly increased its price forecast from $89 to $143. UBS and Goldman Sachs both maintained Buy ratings, lifting their price forecasts from $115 to $155. Keybanc upheld its Overweight rating, adjusting its price forecast from $115 to $145, while Evercore ISI Group maintained an Outperform rating, raising its forecast from $120 to $150. Needham also maintained a Buy rating, increasing its price forecast from $130 to $155. Price Action: ANET stock is trading higher by 18.1% to $139.50 at last check Wednesday. Read Next:Photo via Shutterstock Latest Ratings for ANET Date Firm Action From To Mar 2022 Wells Fargo Upgrades Equal-Weight Overweight Feb 2022 Morgan Stanley Maintains Equal-Weight Feb 2022 Wells Fargo Maintains Equal-Weight View More Analyst Ratings for ANET View the Latest Analyst Ratings Up Next: Transform your trading with Benzinga Edge's one-of-a-kind market trade ideas and tools. Click now to access unique insights that can set you ahead in today's competitive market. Get the latest stock analysis from Benzinga? ARISTA NETWORKS (ANET): Free Stock Analysis Report This article Why Arista Networks Stock Is Skyrocketing Wednesday originally appeared on © 2025 Benzinga does not provide investment advice. All rights reserved. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
